Biocon approves related party deal, sets earnings call

Biocon Limited (BSE: 532523, NSE: BIOCON) announced the successful approval of a material related party transaction(s) between Biocon Biologics UK Limited and Biosimilars Newco Limited, both indirect subsidiaries, via postal ballot. The resolution, as outlined in the notice dated February 26, 2025, garnered significant support, with the voting results and scrutinizer's report now available on Biocon's website and Kfintech. The voting process, conducted electronically, saw 99.9920% of the votes cast in favor of the resolution. The company also announced that the Board of Directors will meet on May 8, 2025, to approve the audited standalone and consolidated financial results for the quarter and fiscal year ending March 31, 2025 and to consider the recommendation of dividend, if any. Following this, an earnings conference call for analysts and investors is scheduled for May 9, 2025, at 09:00 hrs IST, conducted via Zoom; recordings and transcripts will be made available on the Biocon website. The trading window for company insiders is closed from April 1 to May 10, 2025, and will reopen on May 11, 2025.